nodes	percent_of_prediction	percent_of_DWPC	metapath
Roflumilast—Ill-defined disorder—Cisplatin—urinary bladder cancer	0.00311	0.00315	CcSEcCtD
Roflumilast—Renal failure acute—Epirubicin—urinary bladder cancer	0.0031	0.00314	CcSEcCtD
Roflumilast—Dyspepsia—Thiotepa—urinary bladder cancer	0.00307	0.00311	CcSEcCtD
Roflumilast—Myalgia—Gemcitabine—urinary bladder cancer	0.00306	0.0031	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00304	0.00308	CcSEcCtD
Roflumilast—Decreased appetite—Thiotepa—urinary bladder cancer	0.00304	0.00307	CcSEcCtD
Roflumilast—Discomfort—Gemcitabine—urinary bladder cancer	0.00303	0.00306	CcSEcCtD
Roflumilast—Malaise—Cisplatin—urinary bladder cancer	0.00303	0.00306	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00302	0.00305	CcSEcCtD
Roflumilast—Myalgia—Fluorouracil—urinary bladder cancer	0.00301	0.00305	CcSEcCtD
Roflumilast—Fatigue—Thiotepa—urinary bladder cancer	0.00301	0.00305	CcSEcCtD
Roflumilast—Dysgeusia—Etoposide—urinary bladder cancer	0.00301	0.00305	CcSEcCtD
Roflumilast—Constipation—Thiotepa—urinary bladder cancer	0.00299	0.00302	CcSEcCtD
Roflumilast—Discomfort—Fluorouracil—urinary bladder cancer	0.00298	0.00301	CcSEcCtD
Roflumilast—Back pain—Etoposide—urinary bladder cancer	0.00297	0.00301	CcSEcCtD
Roflumilast—Muscle spasms—Etoposide—urinary bladder cancer	0.00296	0.00299	CcSEcCtD
Roflumilast—PDE4D—prostate gland—urinary bladder cancer	0.00294	0.245	CbGeAlD
Roflumilast—Infection—Gemcitabine—urinary bladder cancer	0.00292	0.00295	CcSEcCtD
Roflumilast—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00288	0.00292	CcSEcCtD
Roflumilast—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00288	0.00291	CcSEcCtD
Roflumilast—Infection—Fluorouracil—urinary bladder cancer	0.00287	0.0029	CcSEcCtD
Roflumilast—Renal failure acute—Doxorubicin—urinary bladder cancer	0.00287	0.0029	CcSEcCtD
Roflumilast—Myalgia—Cisplatin—urinary bladder cancer	0.00286	0.00289	CcSEcCtD
Roflumilast—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00286	0.00289	CcSEcCtD
Roflumilast—Skin disorder—Gemcitabine—urinary bladder cancer	0.00285	0.00289	CcSEcCtD
Roflumilast—Ill-defined disorder—Etoposide—urinary bladder cancer	0.00285	0.00289	CcSEcCtD
Roflumilast—Anxiety—Cisplatin—urinary bladder cancer	0.00285	0.00288	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00284	0.00287	CcSEcCtD
Roflumilast—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00283	0.00287	CcSEcCtD
Roflumilast—Discomfort—Cisplatin—urinary bladder cancer	0.00282	0.00286	CcSEcCtD
Roflumilast—Urticaria—Thiotepa—urinary bladder cancer	0.00277	0.00281	CcSEcCtD
Roflumilast—Malaise—Etoposide—urinary bladder cancer	0.00277	0.00281	CcSEcCtD
Roflumilast—Vertigo—Etoposide—urinary bladder cancer	0.00276	0.0028	CcSEcCtD
Roflumilast—Abdominal pain—Thiotepa—urinary bladder cancer	0.00276	0.00279	CcSEcCtD
Roflumilast—Infection—Cisplatin—urinary bladder cancer	0.00272	0.00275	CcSEcCtD
Roflumilast—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00269	0.00272	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00268	0.00271	CcSEcCtD
Roflumilast—Skin disorder—Cisplatin—urinary bladder cancer	0.00266	0.00269	CcSEcCtD
Roflumilast—Insomnia—Gemcitabine—urinary bladder cancer	0.00266	0.00269	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00263	0.00266	CcSEcCtD
Roflumilast—Insomnia—Fluorouracil—urinary bladder cancer	0.00261	0.00264	CcSEcCtD
Roflumilast—PDE4A—prostate gland—urinary bladder cancer	0.0026	0.217	CbGeAlD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.0026	0.00263	CcSEcCtD
Roflumilast—Discomfort—Etoposide—urinary bladder cancer	0.00259	0.00262	CcSEcCtD
Roflumilast—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00257	0.0026	CcSEcCtD
Roflumilast—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00255	0.00258	CcSEcCtD
Roflumilast—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00254	0.00257	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00254	0.00257	CcSEcCtD
Roflumilast—Fatigue—Gemcitabine—urinary bladder cancer	0.00253	0.00256	CcSEcCtD
Roflumilast—Gastritis—Epirubicin—urinary bladder cancer	0.00253	0.00256	CcSEcCtD
Roflumilast—Constipation—Gemcitabine—urinary bladder cancer	0.00251	0.00254	CcSEcCtD
Roflumilast—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00251	0.00254	CcSEcCtD
Roflumilast—Asthenia—Thiotepa—urinary bladder cancer	0.00251	0.00254	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00249	0.00253	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00249	0.00252	CcSEcCtD
Roflumilast—Infection—Etoposide—urinary bladder cancer	0.00249	0.00252	CcSEcCtD
Roflumilast—Influenza—Epirubicin—urinary bladder cancer	0.00247	0.0025	CcSEcCtD
Roflumilast—Skin disorder—Etoposide—urinary bladder cancer	0.00244	0.00247	CcSEcCtD
Roflumilast—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00242	0.00245	CcSEcCtD
Roflumilast—Diarrhoea—Thiotepa—urinary bladder cancer	0.00239	0.00242	CcSEcCtD
Roflumilast—Decreased appetite—Cisplatin—urinary bladder cancer	0.00238	0.00241	CcSEcCtD
Roflumilast—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00238	0.00241	CcSEcCtD
Roflumilast—Pneumonia—Methotrexate—urinary bladder cancer	0.00237	0.0024	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00236	0.00239	CcSEcCtD
Roflumilast—Infestation—Methotrexate—urinary bladder cancer	0.00236	0.00238	CcSEcCtD
Roflumilast—Infestation NOS—Methotrexate—urinary bladder cancer	0.00236	0.00238	CcSEcCtD
Roflumilast—Depression—Methotrexate—urinary bladder cancer	0.00235	0.00238	CcSEcCtD
Roflumilast—Gastritis—Doxorubicin—urinary bladder cancer	0.00234	0.00237	CcSEcCtD
Roflumilast—Dizziness—Thiotepa—urinary bladder cancer	0.00231	0.00234	CcSEcCtD
Roflumilast—Urticaria—Fluorouracil—urinary bladder cancer	0.00229	0.00232	CcSEcCtD
Roflumilast—Influenza—Doxorubicin—urinary bladder cancer	0.00229	0.00232	CcSEcCtD
Roflumilast—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00226	0.00228	CcSEcCtD
Roflumilast—Weight decreased—Epirubicin—urinary bladder cancer	0.00224	0.00226	CcSEcCtD
Roflumilast—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.00223	0.00226	CcSEcCtD
Roflumilast—Vomiting—Thiotepa—urinary bladder cancer	0.00222	0.00225	CcSEcCtD
Roflumilast—Pneumonia—Epirubicin—urinary bladder cancer	0.00222	0.00224	CcSEcCtD
Roflumilast—Infestation NOS—Epirubicin—urinary bladder cancer	0.0022	0.00223	CcSEcCtD
Roflumilast—Infestation—Epirubicin—urinary bladder cancer	0.0022	0.00223	CcSEcCtD
Roflumilast—Rash—Thiotepa—urinary bladder cancer	0.0022	0.00223	CcSEcCtD
Roflumilast—Dermatitis—Thiotepa—urinary bladder cancer	0.0022	0.00223	CcSEcCtD
Roflumilast—Headache—Thiotepa—urinary bladder cancer	0.00219	0.00221	CcSEcCtD
Roflumilast—Decreased appetite—Etoposide—urinary bladder cancer	0.00218	0.00221	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00217	0.00219	CcSEcCtD
Roflumilast—Fatigue—Etoposide—urinary bladder cancer	0.00216	0.00219	CcSEcCtD
Roflumilast—Constipation—Etoposide—urinary bladder cancer	0.00215	0.00217	CcSEcCtD
Roflumilast—Urinary tract infection—Epirubicin—urinary bladder cancer	0.00214	0.00217	CcSEcCtD
Roflumilast—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00213	0.00215	CcSEcCtD
Roflumilast—Asthenia—Gemcitabine—urinary bladder cancer	0.00211	0.00213	CcSEcCtD
Roflumilast—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.00209	0.00211	CcSEcCtD
Roflumilast—Nausea—Thiotepa—urinary bladder cancer	0.00207	0.0021	CcSEcCtD
Roflumilast—Weight decreased—Doxorubicin—urinary bladder cancer	0.00207	0.0021	CcSEcCtD
Roflumilast—Sinusitis—Epirubicin—urinary bladder cancer	0.00207	0.00209	CcSEcCtD
Roflumilast—Feeling abnormal—Etoposide—urinary bladder cancer	0.00207	0.00209	CcSEcCtD
Roflumilast—Pneumonia—Doxorubicin—urinary bladder cancer	0.00205	0.00208	CcSEcCtD
Roflumilast—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00205	0.00208	CcSEcCtD
Roflumilast—Infestation NOS—Doxorubicin—urinary bladder cancer	0.00204	0.00206	CcSEcCtD
Roflumilast—Infestation—Doxorubicin—urinary bladder cancer	0.00204	0.00206	CcSEcCtD
Roflumilast—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00202	0.00204	CcSEcCtD
Roflumilast—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00201	0.00203	CcSEcCtD
Roflumilast—Urticaria—Etoposide—urinary bladder cancer	0.00199	0.00202	CcSEcCtD
Roflumilast—Rhinitis—Epirubicin—urinary bladder cancer	0.00198	0.00201	CcSEcCtD
Roflumilast—Abdominal pain—Etoposide—urinary bladder cancer	0.00198	0.00201	CcSEcCtD
Roflumilast—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.00198	0.00201	CcSEcCtD
Roflumilast—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00198	0.002	CcSEcCtD
Roflumilast—Asthenia—Cisplatin—urinary bladder cancer	0.00196	0.00199	CcSEcCtD
Roflumilast—Cardiac disorder—Methotrexate—urinary bladder cancer	0.00196	0.00199	CcSEcCtD
Roflumilast—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00195	0.00197	CcSEcCtD
Roflumilast—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.00193	0.00195	CcSEcCtD
Roflumilast—Sinusitis—Doxorubicin—urinary bladder cancer	0.00191	0.00194	CcSEcCtD
Roflumilast—Immune system disorder—Methotrexate—urinary bladder cancer	0.00191	0.00193	CcSEcCtD
Roflumilast—Dizziness—Fluorouracil—urinary bladder cancer	0.00191	0.00193	CcSEcCtD
Roflumilast—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.00191	0.00193	CcSEcCtD
Roflumilast—Diarrhoea—Cisplatin—urinary bladder cancer	0.00187	0.0019	CcSEcCtD
Roflumilast—Vomiting—Gemcitabine—urinary bladder cancer	0.00187	0.00189	CcSEcCtD
Roflumilast—Mental disorder—Methotrexate—urinary bladder cancer	0.00185	0.00188	CcSEcCtD
Roflumilast—Rash—Gemcitabine—urinary bladder cancer	0.00185	0.00187	CcSEcCtD
Roflumilast—Dermatitis—Gemcitabine—urinary bladder cancer	0.00185	0.00187	CcSEcCtD
Roflumilast—Hypersensitivity—Etoposide—urinary bladder cancer	0.00185	0.00187	CcSEcCtD
Roflumilast—Malnutrition—Methotrexate—urinary bladder cancer	0.00184	0.00186	CcSEcCtD
Roflumilast—Headache—Gemcitabine—urinary bladder cancer	0.00184	0.00186	CcSEcCtD
Roflumilast—Cardiac disorder—Epirubicin—urinary bladder cancer	0.00184	0.00186	CcSEcCtD
Roflumilast—Vomiting—Fluorouracil—urinary bladder cancer	0.00184	0.00186	CcSEcCtD
Roflumilast—Rhinitis—Doxorubicin—urinary bladder cancer	0.00184	0.00186	CcSEcCtD
Roflumilast—Rash—Fluorouracil—urinary bladder cancer	0.00182	0.00184	CcSEcCtD
Roflumilast—Dermatitis—Fluorouracil—urinary bladder cancer	0.00182	0.00184	CcSEcCtD
Roflumilast—Headache—Fluorouracil—urinary bladder cancer	0.00181	0.00183	CcSEcCtD
Roflumilast—Dysgeusia—Methotrexate—urinary bladder cancer	0.0018	0.00182	CcSEcCtD
Roflumilast—Asthenia—Etoposide—urinary bladder cancer	0.0018	0.00182	CcSEcCtD
Roflumilast—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.0018	0.00182	CcSEcCtD
Roflumilast—Immune system disorder—Epirubicin—urinary bladder cancer	0.00179	0.00181	CcSEcCtD
Roflumilast—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.00178	0.00181	CcSEcCtD
Roflumilast—Back pain—Methotrexate—urinary bladder cancer	0.00178	0.0018	CcSEcCtD
Roflumilast—Nausea—Gemcitabine—urinary bladder cancer	0.00175	0.00177	CcSEcCtD
Roflumilast—Vomiting—Cisplatin—urinary bladder cancer	0.00174	0.00176	CcSEcCtD
Roflumilast—Mental disorder—Epirubicin—urinary bladder cancer	0.00173	0.00176	CcSEcCtD
Roflumilast—Rash—Cisplatin—urinary bladder cancer	0.00173	0.00175	CcSEcCtD
Roflumilast—Dermatitis—Cisplatin—urinary bladder cancer	0.00173	0.00175	CcSEcCtD
Roflumilast—Malnutrition—Epirubicin—urinary bladder cancer	0.00172	0.00174	CcSEcCtD
Roflumilast—Diarrhoea—Etoposide—urinary bladder cancer	0.00172	0.00174	CcSEcCtD
Roflumilast—Nausea—Fluorouracil—urinary bladder cancer	0.00172	0.00174	CcSEcCtD
Roflumilast—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00171	0.00173	CcSEcCtD
Roflumilast—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.0017	0.00172	CcSEcCtD
Roflumilast—Tension—Epirubicin—urinary bladder cancer	0.00169	0.00171	CcSEcCtD
Roflumilast—Dysgeusia—Epirubicin—urinary bladder cancer	0.00169	0.00171	CcSEcCtD
Roflumilast—Nervousness—Epirubicin—urinary bladder cancer	0.00167	0.00169	CcSEcCtD
Roflumilast—Back pain—Epirubicin—urinary bladder cancer	0.00167	0.00169	CcSEcCtD
Roflumilast—Malaise—Methotrexate—urinary bladder cancer	0.00166	0.00168	CcSEcCtD
Roflumilast—Dizziness—Etoposide—urinary bladder cancer	0.00166	0.00168	CcSEcCtD
Roflumilast—Muscle spasms—Epirubicin—urinary bladder cancer	0.00166	0.00168	CcSEcCtD
Roflumilast—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00165	0.00167	CcSEcCtD
Roflumilast—Vertigo—Methotrexate—urinary bladder cancer	0.00165	0.00167	CcSEcCtD
Roflumilast—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.00165	0.00167	CcSEcCtD
Roflumilast—Nausea—Cisplatin—urinary bladder cancer	0.00163	0.00165	CcSEcCtD
Roflumilast—Mental disorder—Doxorubicin—urinary bladder cancer	0.0016	0.00162	CcSEcCtD
Roflumilast—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.0016	0.00162	CcSEcCtD
Roflumilast—Vomiting—Etoposide—urinary bladder cancer	0.0016	0.00161	CcSEcCtD
Roflumilast—Malnutrition—Doxorubicin—urinary bladder cancer	0.00159	0.00161	CcSEcCtD
Roflumilast—Rash—Etoposide—urinary bladder cancer	0.00158	0.0016	CcSEcCtD
Roflumilast—Dermatitis—Etoposide—urinary bladder cancer	0.00158	0.0016	CcSEcCtD
Roflumilast—Headache—Etoposide—urinary bladder cancer	0.00157	0.00159	CcSEcCtD
Roflumilast—Myalgia—Methotrexate—urinary bladder cancer	0.00157	0.00159	CcSEcCtD
Roflumilast—Tension—Doxorubicin—urinary bladder cancer	0.00156	0.00158	CcSEcCtD
Roflumilast—Dysgeusia—Doxorubicin—urinary bladder cancer	0.00156	0.00158	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.00156	0.00158	CcSEcCtD
Roflumilast—Malaise—Epirubicin—urinary bladder cancer	0.00155	0.00157	CcSEcCtD
Roflumilast—PDE4B—prostate gland—urinary bladder cancer	0.00155	0.129	CbGeAlD
Roflumilast—Discomfort—Methotrexate—urinary bladder cancer	0.00155	0.00157	CcSEcCtD
Roflumilast—Nervousness—Doxorubicin—urinary bladder cancer	0.00155	0.00157	CcSEcCtD
Roflumilast—Vertigo—Epirubicin—urinary bladder cancer	0.00155	0.00157	CcSEcCtD
Roflumilast—Back pain—Doxorubicin—urinary bladder cancer	0.00154	0.00156	CcSEcCtD
Roflumilast—Muscle spasms—Doxorubicin—urinary bladder cancer	0.00153	0.00155	CcSEcCtD
Roflumilast—Palpitations—Epirubicin—urinary bladder cancer	0.00152	0.00154	CcSEcCtD
Roflumilast—Infection—Methotrexate—urinary bladder cancer	0.00149	0.00151	CcSEcCtD
Roflumilast—Nausea—Etoposide—urinary bladder cancer	0.00149	0.00151	CcSEcCtD
Roflumilast—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.00148	0.0015	CcSEcCtD
Roflumilast—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00147	0.00149	CcSEcCtD
Roflumilast—Myalgia—Epirubicin—urinary bladder cancer	0.00147	0.00148	CcSEcCtD
Roflumilast—Anxiety—Epirubicin—urinary bladder cancer	0.00146	0.00148	CcSEcCtD
Roflumilast—Skin disorder—Methotrexate—urinary bladder cancer	0.00146	0.00148	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00146	0.00147	CcSEcCtD
Roflumilast—Discomfort—Epirubicin—urinary bladder cancer	0.00145	0.00147	CcSEcCtD
Roflumilast—Malaise—Doxorubicin—urinary bladder cancer	0.00144	0.00146	CcSEcCtD
Roflumilast—Vertigo—Doxorubicin—urinary bladder cancer	0.00143	0.00145	CcSEcCtD
Roflumilast—Palpitations—Doxorubicin—urinary bladder cancer	0.00141	0.00143	CcSEcCtD
Roflumilast—Infection—Epirubicin—urinary bladder cancer	0.0014	0.00141	CcSEcCtD
Roflumilast—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00138	0.0014	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.00137	0.00139	CcSEcCtD
Roflumilast—Skin disorder—Epirubicin—urinary bladder cancer	0.00137	0.00138	CcSEcCtD
Roflumilast—Insomnia—Methotrexate—urinary bladder cancer	0.00136	0.00138	CcSEcCtD
Roflumilast—Myalgia—Doxorubicin—urinary bladder cancer	0.00136	0.00137	CcSEcCtD
Roflumilast—Anxiety—Doxorubicin—urinary bladder cancer	0.00135	0.00137	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00135	0.00136	CcSEcCtD
Roflumilast—Discomfort—Doxorubicin—urinary bladder cancer	0.00134	0.00136	CcSEcCtD
Roflumilast—Dyspepsia—Methotrexate—urinary bladder cancer	0.00132	0.00134	CcSEcCtD
Roflumilast—Decreased appetite—Methotrexate—urinary bladder cancer	0.00131	0.00132	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.0013	0.00131	CcSEcCtD
Roflumilast—Fatigue—Methotrexate—urinary bladder cancer	0.0013	0.00131	CcSEcCtD
Roflumilast—Infection—Doxorubicin—urinary bladder cancer	0.00129	0.00131	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00128	0.0013	CcSEcCtD
Roflumilast—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00128	0.00129	CcSEcCtD
Roflumilast—Insomnia—Epirubicin—urinary bladder cancer	0.00127	0.00129	CcSEcCtD
Roflumilast—Skin disorder—Doxorubicin—urinary bladder cancer	0.00126	0.00128	CcSEcCtD
Roflumilast—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00124	0.00125	CcSEcCtD
Roflumilast—Dyspepsia—Epirubicin—urinary bladder cancer	0.00124	0.00125	CcSEcCtD
Roflumilast—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00123	0.00124	CcSEcCtD
Roflumilast—Decreased appetite—Epirubicin—urinary bladder cancer	0.00122	0.00124	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00121	0.00123	CcSEcCtD
Roflumilast—Fatigue—Epirubicin—urinary bladder cancer	0.00121	0.00123	CcSEcCtD
Roflumilast—Constipation—Epirubicin—urinary bladder cancer	0.0012	0.00122	CcSEcCtD
Roflumilast—Urticaria—Methotrexate—urinary bladder cancer	0.00119	0.00121	CcSEcCtD
Roflumilast—Abdominal pain—Methotrexate—urinary bladder cancer	0.00119	0.0012	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.00119	0.0012	CcSEcCtD
Roflumilast—Insomnia—Doxorubicin—urinary bladder cancer	0.00118	0.00119	CcSEcCtD
Roflumilast—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00116	0.00117	CcSEcCtD
Roflumilast—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.00115	0.00116	CcSEcCtD
Roflumilast—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00115	0.00116	CcSEcCtD
Roflumilast—Decreased appetite—Doxorubicin—urinary bladder cancer	0.00113	0.00114	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00112	0.00114	CcSEcCtD
Roflumilast—Fatigue—Doxorubicin—urinary bladder cancer	0.00112	0.00114	CcSEcCtD
Roflumilast—Urticaria—Epirubicin—urinary bladder cancer	0.00112	0.00113	CcSEcCtD
Roflumilast—Constipation—Doxorubicin—urinary bladder cancer	0.00111	0.00113	CcSEcCtD
Roflumilast—Abdominal pain—Epirubicin—urinary bladder cancer	0.00111	0.00113	CcSEcCtD
Roflumilast—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00111	0.00112	CcSEcCtD
Roflumilast—Asthenia—Methotrexate—urinary bladder cancer	0.00108	0.00109	CcSEcCtD
Roflumilast—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.00107	0.00109	CcSEcCtD
Roflumilast—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.00106	0.00108	CcSEcCtD
Roflumilast—PDE4B—urethra—urinary bladder cancer	0.00104	0.0865	CbGeAlD
Roflumilast—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00104	0.00105	CcSEcCtD
Roflumilast—Urticaria—Doxorubicin—urinary bladder cancer	0.00103	0.00105	CcSEcCtD
Roflumilast—Abdominal pain—Doxorubicin—urinary bladder cancer	0.00103	0.00104	CcSEcCtD
Roflumilast—Diarrhoea—Methotrexate—urinary bladder cancer	0.00103	0.00104	CcSEcCtD
Roflumilast—Asthenia—Epirubicin—urinary bladder cancer	0.00101	0.00102	CcSEcCtD
Roflumilast—Dizziness—Methotrexate—urinary bladder cancer	0.000994	0.00101	CcSEcCtD
Roflumilast—Diarrhoea—Epirubicin—urinary bladder cancer	0.000962	0.000974	CcSEcCtD
Roflumilast—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000959	0.00097	CcSEcCtD
Roflumilast—Vomiting—Methotrexate—urinary bladder cancer	0.000955	0.000967	CcSEcCtD
Roflumilast—Rash—Methotrexate—urinary bladder cancer	0.000947	0.000959	CcSEcCtD
Roflumilast—Dermatitis—Methotrexate—urinary bladder cancer	0.000947	0.000958	CcSEcCtD
Roflumilast—Headache—Methotrexate—urinary bladder cancer	0.000941	0.000953	CcSEcCtD
Roflumilast—PDE4D—lymph node—urinary bladder cancer	0.000939	0.0782	CbGeAlD
Roflumilast—Asthenia—Doxorubicin—urinary bladder cancer	0.000934	0.000945	CcSEcCtD
Roflumilast—Dizziness—Epirubicin—urinary bladder cancer	0.00093	0.000941	CcSEcCtD
Roflumilast—Vomiting—Epirubicin—urinary bladder cancer	0.000894	0.000905	CcSEcCtD
Roflumilast—Nausea—Methotrexate—urinary bladder cancer	0.000893	0.000903	CcSEcCtD
Roflumilast—Diarrhoea—Doxorubicin—urinary bladder cancer	0.00089	0.000901	CcSEcCtD
Roflumilast—Rash—Epirubicin—urinary bladder cancer	0.000887	0.000897	CcSEcCtD
Roflumilast—Dermatitis—Epirubicin—urinary bladder cancer	0.000886	0.000897	CcSEcCtD
Roflumilast—Headache—Epirubicin—urinary bladder cancer	0.000881	0.000892	CcSEcCtD
Roflumilast—Dizziness—Doxorubicin—urinary bladder cancer	0.00086	0.000871	CcSEcCtD
Roflumilast—PDE4B—female reproductive system—urinary bladder cancer	0.000847	0.0705	CbGeAlD
Roflumilast—Nausea—Epirubicin—urinary bladder cancer	0.000835	0.000845	CcSEcCtD
Roflumilast—PDE4A—lymph node—urinary bladder cancer	0.000831	0.0692	CbGeAlD
Roflumilast—Vomiting—Doxorubicin—urinary bladder cancer	0.000827	0.000837	CcSEcCtD
Roflumilast—Rash—Doxorubicin—urinary bladder cancer	0.00082	0.00083	CcSEcCtD
Roflumilast—Dermatitis—Doxorubicin—urinary bladder cancer	0.00082	0.00083	CcSEcCtD
Roflumilast—Headache—Doxorubicin—urinary bladder cancer	0.000815	0.000825	CcSEcCtD
Roflumilast—Nausea—Doxorubicin—urinary bladder cancer	0.000773	0.000782	CcSEcCtD
Roflumilast—PDE4B—vagina—urinary bladder cancer	0.000766	0.0638	CbGeAlD
Roflumilast—PDE4B—lymph node—urinary bladder cancer	0.000495	0.0413	CbGeAlD
